Discovery of potent and specific fructose-1,6-bisphosphatase inhibitors and a series of orally-bioavailable phosphoramidase-sensitive prodrugs for the treatment of type 2 diabetes.

@article{Dang2007DiscoveryOP,
  title={Discovery of potent and specific fructose-1,6-bisphosphatase inhibitors and a series of orally-bioavailable phosphoramidase-sensitive prodrugs for the treatment of type 2 diabetes.},
  author={Qun Dang and Srinivas Rao Kasibhatla and K. Raveendranath Reddy and Tao Jiang and Maram Rami Reddy and Scott C. Potter and James M. Fujitaki and Paul D van Poelje and Jingwei Huang and William Nunn Lipscomb and Mark D. Erion},
  journal={Journal of the American Chemical Society},
  year={2007},
  volume={129 50},
  pages={
          15491-502
        }
}
Excessive glucose production by the liver coupled with decreased glucose uptake and metabolism by muscle, fat, and liver results in chronically elevated blood glucose levels in patients with type 2 diabetes. Efforts to treat diabetes by reducing glucose production have largely focused on the gluconeogenesis pathway and rate-limiting enzymes within this pathway such as fructose-1,6-bisphosphatase (FBPase). The first potent FBPase inhibitors were identified using a structure-guided drug design… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 25 CITATIONS

Metformin attenuates olanzapine-induced hepatic, but not peripheral insulin resistance.

  • The Journal of endocrinology
  • 2015
VIEW 7 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Identification of activating enzymes of a novel FBPase inhibitor prodrug, CS-917

  • Pharmacology research & perspectives
  • 2015
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Targeting FBPase is an emerging novel approach for cancer therapy

  • Cancer Cell International
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND